Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ferran Vall-Llovera

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Revista Espanola De Enfermedades Digestivas|February 22, 2021
Clinical impact of endoscopic ultrasound in the study of adrenal gland: cytomegalovirus infection mimicking a neoplasic hypercaptation in PETAlbert Martín-Cardona, Ferran Vall-Llovera Calmet, Clarisa González Mínguez, et al.
Haematologica|January 2, 2008
Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAARTJosé-Tomás Navarro, Ferran Vall-Llovera, José-Luis Mate, et al.
Medicina Clinica|November 17, 2007
[Neutropenic enterocolitis in adult patients with acute leukemia or stem cell transplant recipients: study of 7 cases]Montserrat Batlle, Ferran Vall-Llovera, Jordi Bechini, et al.
Leukemia & Lymphoma|January 18, 2013
Pharmacogenetic analysis in the treatment of Hodgkin lymphomaAlbert Altés, Laia Paré, Albert Esquirol, et al.
Oncotarget|May 4, 2018
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidineMarta Cabezón, Joan Bargay, Blanca Xicoy, et al.
Blood Cancer Journal|May 5, 2023
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohortGuadalupe Oñate, Marta Pratcorona, Ana Garrido, et al.
Cancer|January 31, 2013
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)Josep-Maria Ribera, Olga García, Carlos Grande, et al.
Blood Cancer Journal|January 11, 2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM GroupGuadalupe Oñate, Ana Garrido, Montserrat Arnan, et al.
British Journal of Haematology|June 9, 2020
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual diseaseAlex Bataller, Guadalupe Oñate, Marina Diaz-Beyá, et al.
European Journal of Haematology|September 5, 2022
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogeneticsJohana Díaz-Santa, Rocío Rodríguez-Romanos, Rosa Coll, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Revista Espanola De Enfermedades Digestivas|February 22, 2021
Clinical impact of endoscopic ultrasound in the study of adrenal gland: cytomegalovirus infection mimicking a neoplasic hypercaptation in PETAlbert Martín-Cardona, Ferran Vall-Llovera Calmet, Clarisa González Mínguez, et al.
Haematologica|January 2, 2008
Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAARTJosé-Tomás Navarro, Ferran Vall-Llovera, José-Luis Mate, et al.
Medicina Clinica|November 17, 2007
[Neutropenic enterocolitis in adult patients with acute leukemia or stem cell transplant recipients: study of 7 cases]Montserrat Batlle, Ferran Vall-Llovera, Jordi Bechini, et al.
Leukemia & Lymphoma|January 18, 2013
Pharmacogenetic analysis in the treatment of Hodgkin lymphomaAlbert Altés, Laia Paré, Albert Esquirol, et al.
Oncotarget|May 4, 2018
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidineMarta Cabezón, Joan Bargay, Blanca Xicoy, et al.
Blood Cancer Journal|May 5, 2023
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohortGuadalupe Oñate, Marta Pratcorona, Ana Garrido, et al.
Cancer|January 31, 2013
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)Josep-Maria Ribera, Olga García, Carlos Grande, et al.
Blood Cancer Journal|January 11, 2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM GroupGuadalupe Oñate, Ana Garrido, Montserrat Arnan, et al.
British Journal of Haematology|June 9, 2020
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual diseaseAlex Bataller, Guadalupe Oñate, Marina Diaz-Beyá, et al.
European Journal of Haematology|September 5, 2022
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogeneticsJohana Díaz-Santa, Rocío Rodríguez-Romanos, Rosa Coll, et al.
Pageof 3